Fluorescent imaging agent - CEA-Leti/NICE Consortium

Drug Profile

Fluorescent imaging agent - CEA-Leti/NICE Consortium

Alternative Names: LipImage 815

Latest Information Update: 17 Jul 2013

Price : $50

At a glance

  • Originator CEA-LETI
  • Developer NICE Consortium
  • Class Imaging agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Liver cancer

Most Recent Events

  • 03 Jul 2013 Preclinical trials in Liver cancer (diagnosis) in France (Parenteral)
  • 03 Jul 2013 CEA-Leti receives grant from bpifrance for Lipimage 815™ development in Liver cancer (diagnosis)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top